EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call and live webcast on November 2, 2022, at 8:30 a.m. ET to report its Q3 2022 financial results and discuss corporate developments. The company focuses on developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained intraocular drug delivery. Currently, EYPT is advancing EYP-1901, a Phase 2 clinical trial treatment. The call will be accessible via a registration link and a replay will be available on the company's website after the event.

Positive

• Company is advancing EYP-1901 in Phase 2 clinical trials.
• Durasert technology has been used safely in thousands of patients.

Negative

• None.

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/nb4wzrzt. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:
Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will EyePoint Pharmaceuticals announce its Q3 2022 financial results?

EyePoint Pharmaceuticals will announce its Q3 2022 financial results on November 2, 2022.

What is EYP-1901 and its current status?

EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials.

How can I listen to the conference call for EyePoint Pharmaceuticals?

You can listen to the conference call by registering through the provided audio conference link or via the Investors section on the company's website.